Fairvalue-Calculator Fairvalue-Calculator
EN DE

Botanix Pharmaceuticals Limited (BOT) Fair Value & Analysis

Healthcare · AU · Market cap A$59.8M

PriceA$0.0190
Fair ValueA$0.0173
Upside-9.0%
Quality95/100
Evidence: Low Range A$0.0173 – A$0.0173

Fair value as of: Jun 26, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Botanix Pharmaceuticals Limited (BOT) currently trades at A$0.0190, while our model-based Fair Value estimate is A$0.0173 — implying the stock looks roughly 9.0% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Botanix Pharmaceuticals Limited operates as a commercial dermatology company in Australia and the United States. The company's lead product is Sofdra (sofpironium) topical gel, a prescription anticholinergic medicine used on the skin to treat underarm sweating in adults and children 9 years of age and older. Its product pipeline includes BTX 1503, a transdermal gel formulation for the treatment of serious acne in adults and teenagers; BTX 1801 for treating staphylococcus aureus and methicillin resistant staphylococcus aureus; BTX 1702 for the treatment of papulopustular rosacea; and BTX 1204A for treating atopic dermatitis. The company was incorporated in 1984 and is based in Melbourne, Australia.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -88% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -23% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -62%

Frequently asked questions

Is Botanix Pharmaceuticals Limited (BOT) undervalued?
As of Jun 26, 2026, our model estimates a fair value of A$0.0173 versus a price of A$0.0190 — about −9% (overvalued). Model-based estimate, not financial advice.
What is the fair value of BOT?
Our 21-model fair value for Botanix Pharmaceuticals Limited is A$0.0173 (as of Jun 26, 2026), built from audited fundamentals. The current price is A$0.0190.
What is the quality score of BOT?
Botanix Pharmaceuticals Limited has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.